Mipharm S.p.A. was born in January 1998 following the merger of Sandoz and Ciba Geigy, from which resulted the new company Novartis. Mipharm was founded by a group of ex managers coming from Novartis by mean of a spin-off of the manufacturing site located in Milan, Via Quaranta, previously owned by Sandoz.
In December 2016, Mandarin Capital Partners II acquired the majority stake in Mipharm share capital.
Today, Mipharm is one of the most valuable third party manufacturing and new product development sites in Italy and it claims to have four FDA approvals (Nasal Spray Solution, Oral Potent Drug, Sachet, Packaging).
Mipharm has been investing significant resources to continuously improve manufacturing site qualitative standard and currently it is able to produce and to pack a huge range of products and pharmaceutical forms.
Company Details
- Employees
- 202
- Founded
- -
- Address
- Via Bernardo Quaranta 12, Milan,lombardia 20141,italy
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- mipharm.it
- HQ
- Milan, Lombardia
Mipharm Spa Questions
Mipharm Spa's website is mipharm.it
Mipharm Spa's LinkedIn profile is https://it.linkedin.com/company/mipharm-s.p.a.
Mipharm Spa has
202 employees.
View email and phone details for 202
employees at Mipharm Spa.
Mipharm Spa's industry is
Pharmaceutical Manufacturing
Mipharm Spa's top competitors are
Flamma Group,
Indena,
Olon,
Fidia Pharma,
Doppel Farmaceutici,
Ibsa Italy,
Dipharma Francis S.r.l,
Acs Dobfar,
Alfasigma,
Dompé.
Mipharm Spa's categories are Pharmaceutical Manufacturing
Mipharm Spa's founding year is 1998
